Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand

J. Brooks Jackson; Liu Wei; Fu Liping; Apinun Aramrattana; David D Celentano; Louise Walshe; Yi Xing; Paul Richardson; Ma Jun; Geetha Beauchamp; Deborah Donnell; Yuhua Ruan; Liying Ma; David Metzger; Yiming Shao

doi:10.1155/2014/296958

Back

Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand

Journal article

Open access

Peer reviewed

Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand

J. Brooks Jackson, Liu Wei, Fu Liping, Apinun Aramrattana, David D Celentano, Louise Walshe, Yi Xing, Paul Richardson, Ma Jun, Geetha Beauchamp, …

Hepatitis research and treatment, Vol.2014(2014), pp.1-5

2014

DOI: 10.1155/2014/296958

PMCID: PMC3985324

PMID: 24860664

Files and links (1)

url

https://doi.org/10.1155/2014/296958View

Published (Version of record) Open Access

Abstract

We determined the prevalence and incidence of HBV and HCV infection in people who inject drugs (PWIDs) at high risk for HIV in China and Thailand and determined the association of HBV and HCV incidence with urine opiate test results and with short-term versus long-term buprenorphine-naloxone (B-N) treatment use in a randomized clinical trial (HPTN 058). 13.8% of 1049 PWIDs in China and 13.9% of 201 PWIDs in Thailand were HBsAg positive at baseline. Among HBsAg negative participants, the HBsAg incidence rate was 2.7/100 person years in China and 0/100 person years in Thailand. 81.9% of 1049 PWIDs in China and 59.7% of 201 in Thailand were HCV antibody positive at baseline. The HCV confirmed seroincidence rate among HCV antibody negative PWIDs was 22/100 person years in China and 4.6/100 person years in Thailand. Incident HBsAg was not significantly different in the short-term versus long-term B-N arm in China or Thailand. Participants with positive opiate results in at least 75% of their urines during the time period were at increased risk of incident HBsAg (HR = 5.22; 95% CI, 1.08 to 25.22; P=0.04) in China, but not incident HCV conversion in China or Thailand.

Details

Title: Subtitle: Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand
Creators: J. Brooks Jackson - Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
Liu Wei - Guangxi Center for Disease Control and Prevention, Nanning 530028, China
Fu Liping - Xinjiang Center for Disease Control and Prevention, Urumqi 83001, China
Apinun Aramrattana - Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
David D Celentano - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Louise Walshe - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Yi Xing - Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
Paul Richardson - Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA
Ma Jun - Xinjiang Center for Disease Control and Prevention, Urumqi 83001, China
Geetha Beauchamp - Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Deborah Donnell - Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Yuhua Ruan - State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing 102206, China
Liying Ma - State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing 102206, China
David Metzger - University of Pennsylvania, Philadelphia, PA 19104, USA
Yiming Shao - State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing 102206, China
Resource Type: Journal article
Publication Details: Hepatitis research and treatment, Vol.2014(2014), pp.1-5
DOI: 10.1155/2014/296958
PMID: 24860664
PMCID: PMC3985324
NLM abbreviation: Hepat Res Treat
ISSN: 2090-1364
eISSN: 2090-1372
Grant note: DOI: 10.13039/100000060, name: National Institute of Allergy and Infectious Diseases, award: UM1 068619, UM1-AI-069482, UM1-AI-069406, UM1-AI068613, UMI-AI-069411
Language: English
Date published: 2014
Academic Unit: Pathology; VPMA - Administration
Record Identifier: 9984046910802771

Metrics

14 Record Views